242 related articles for article (PubMed ID: 34517871)
1. Mapping the PHQ-8 to EQ-5D, HUI3 and SF6D in patients with depression.
Abdin E; Chong SA; Seow E; Tan KB; Subramaniam M
BMC Psychiatry; 2021 Sep; 21(1):451. PubMed ID: 34517871
[TBL] [Abstract][Full Text] [Related]
2. Mapping the schizophrenia quality of life scale to EQ-5D, HUI3 and SF-6D utility scores in patients with schizophrenia.
Seow LSE; Lau JH; Abdin E; Verma SK; Tan KB; Subramaniam M
Expert Rev Pharmacoecon Outcomes Res; 2023; 23(7):813-821. PubMed ID: 37216213
[TBL] [Abstract][Full Text] [Related]
3. Mapping the Positive and Negative Syndrome Scale scores to EQ-5D-5L and SF-6D utility scores in patients with schizophrenia.
Abdin E; Chong SA; Seow E; Verma S; Tan KB; Subramaniam M
Qual Life Res; 2019 Jan; 28(1):177-186. PubMed ID: 30382480
[TBL] [Abstract][Full Text] [Related]
4. Testing alternative regression models to predict utilities: mapping the QLQ-C30 onto the EQ-5D-5L and the SF-6D.
Lamu AN; Olsen JA
Qual Life Res; 2018 Nov; 27(11):2823-2839. PubMed ID: 30173314
[TBL] [Abstract][Full Text] [Related]
5. Using the Multiple Sclerosis Impact Scale to estimate health state utility values: mapping from the MSIS-29, version 2, to the EQ-5D and the SF-6D.
Hawton A; Green C; Telford C; Zajicek J; Wright D
Value Health; 2012 Dec; 15(8):1084-91. PubMed ID: 23244811
[TBL] [Abstract][Full Text] [Related]
6. Mapping MOS-HIV to HUI3 and EQ-5D-3L in Patients With HIV.
Joyce VR; Sun H; Barnett PG; Bansback N; Griffin SC; Bayoumi AM; Anis AH; Sculpher M; Cameron W; Brown ST; Holodniy M; Owens DK
MDM Policy Pract; 2017; 2(2):2381468317716440. PubMed ID: 30288427
[No Abstract] [Full Text] [Related]
7. A vision 'bolt-on' increases the responsiveness of EQ-5D: preliminary evidence from a study of cataract surgery.
Gandhi M; Ang M; Teo K; Wong CW; Wei YC; Tan RL; Janssen MF; Luo N
Eur J Health Econ; 2020 Jun; 21(4):501-511. PubMed ID: 31902023
[TBL] [Abstract][Full Text] [Related]
8. EQ-5D-5L is More Responsive than EQ-5D-3L to Treatment Benefit of Cataract Surgery.
Gandhi M; Ang M; Teo K; Wong CW; Wei YC; Tan RL; Janssen MF; Luo N
Patient; 2019 Aug; 12(4):383-392. PubMed ID: 30607809
[TBL] [Abstract][Full Text] [Related]
9. Mapping the Chinese Version of the EORTC QLQ-BR53 Onto the EQ-5D-5L and SF-6D Utility Scores.
Liu T; Li S; Wang M; Sun Q; Chen G
Patient; 2020 Oct; 13(5):537-555. PubMed ID: 32382953
[TBL] [Abstract][Full Text] [Related]
10. Mapping ALSFRS-R and ALSUI to EQ-5D in Patients with Motor Neuron Disease.
Moore A; Young CA; Hughes DA
Value Health; 2018 Nov; 21(11):1322-1329. PubMed ID: 30442280
[TBL] [Abstract][Full Text] [Related]
11. Mapping between the Roland Morris Questionnaire and generic preference-based measures.
Khan KA; Madan J; Petrou S; Lamb SE
Value Health; 2014 Sep; 17(6):686-95. PubMed ID: 25236992
[TBL] [Abstract][Full Text] [Related]
12. Mapping the cancer-specific QLQ-C30 onto the generic EQ-5D-5L and SF-6D in colorectal cancer patients.
Ameri H; Yousefi M; Yaseri M; Nahvijou A; Arab M; Akbari Sari A
Expert Rev Pharmacoecon Outcomes Res; 2019 Feb; 19(1):89-96. PubMed ID: 30173585
[TBL] [Abstract][Full Text] [Related]
13. Differential Psychometric Properties of EuroQoL 5-Dimension 5-Level and Short-Form 6-Dimension Utility Measures in Low Back Pain.
Cheung PWH; Wong CKH; Cheung JPY
Spine (Phila Pa 1976); 2019 Jun; 44(11):E679-E686. PubMed ID: 30475342
[TBL] [Abstract][Full Text] [Related]
14. Mapping QLQ-C30 Onto EQ-5D-5L and SF-6D-V2 in Patients With Colorectal and Breast Cancer From a Developing Country.
Yousefi M; Nahvijou A; Sari AA; Ameri H
Value Health Reg Issues; 2021 May; 24():57-66. PubMed ID: 33508752
[TBL] [Abstract][Full Text] [Related]
15. EQ-5D-5L and SF-6D Utility Measures in Symptomatic benign Thyroid Nodules: Acceptability and Psychometric Evaluation.
Wong CKH; Lang BHH; Yu HMS; Lam CLK
Patient; 2017 Aug; 10(4):447-454. PubMed ID: 28224296
[TBL] [Abstract][Full Text] [Related]
16. A review of the psychometric properties of generic utility measures in multiple sclerosis.
Kuspinar A; Mayo NE
Pharmacoeconomics; 2014 Aug; 32(8):759-73. PubMed ID: 24846760
[TBL] [Abstract][Full Text] [Related]
17. Mapping the SRS-22r questionnaire onto the EQ-5D-5L utility score in patients with adolescent idiopathic scoliosis.
Wong CKH; Cheung PWH; Samartzis D; Luk KD; Cheung KMC; Lam CLK; Cheung JPY
PLoS One; 2017; 12(4):e0175847. PubMed ID: 28414745
[TBL] [Abstract][Full Text] [Related]
18. Mapping the FACT-G cancer-specific quality of life instrument to the EQ-5D and SF-6D.
Teckle P; McTaggart-Cowan H; Van der Hoek K; Chia S; Melosky B; Gelmon K; Peacock S
Health Qual Life Outcomes; 2013 Dec; 11():203. PubMed ID: 24289488
[TBL] [Abstract][Full Text] [Related]
19. Does Selecting Covariates Using Factor Analysis in Mapping Algorithms Improve Predictive Accuracy? A Case of Predicting EQ-5D-5L and SF-6D Utilities from the Women's Health Questionnaire.
Kaambwa B; Smith C; de Lacey S; Ratcliffe J
Value Health; 2018 Oct; 21(10):1205-1217. PubMed ID: 30314622
[TBL] [Abstract][Full Text] [Related]
20. Use of generic and condition-specific measures of health-related quality of life in NICE decision-making: a systematic review, statistical modelling and survey.
Longworth L; Yang Y; Young T; Mulhern B; Hernández Alava M; Mukuria C; Rowen D; Tosh J; Tsuchiya A; Evans P; Devianee Keetharuth A; Brazier J
Health Technol Assess; 2014 Feb; 18(9):1-224. PubMed ID: 24524660
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]